Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.54 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.49 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379784 | 0.86 | HSP90B1 (0.45) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL383211 | 0.85 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL383083 | 0.82 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL383810 | 0.81 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL19339221 | 0.81 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL10268436 | 0.78 | HRH3 (0.46) | HSP90B1TRAP1 | |
| SCHEMBL10269548 | 0.75 | ABHD6 (0.50) | — | |
| SCHEMBL4257425 | 0.75 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL384701 | 0.75 | ABCB1 (0.44) | HSP90B1TRAP1 | |
| SCHEMBL383317 | 0.74 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | claimed |
| EP-1877379-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2013-01-16 | — | — | EP | claimed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | claimed |
| EP-2332909-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | Astex Therapeutics Limited (GB) | 2011-06-15 | — | — | EP | claimed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | claimed |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-15 | — | — | US | claimed |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | US | claimed |
| EP-2073802-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073804-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073807-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073803-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | claimed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| EP-0905139-A2 | 5 ring heterocyles, process for preparation, use as inhibitors of leukocyte adhesion and pharmaceutical preparations comprising them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | HSP90AB1, HEATR6, HEATR1 | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 7/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | HSP90AA1 105/4885HSP90AB1 49/4885HSP90B1 86/4885 |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | H1-10, C1R, C1S | HSP90AA1 3726/4885HSP90AB1 4036/4885HSP90B1 3671/4885 |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, CDK6 | HSP90AA1 68/4885HSP90AB1 23/4885HSP90B1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.